Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia
Authors:
- 4 September 2023
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (13) , 2091-2100
Abstract
Selinexor, an oral inhibitor of the nuclear transport protein Exportin-1, shows promising single-agent activity in clinical trials of relapsed/refractory (R/R) acute myeloid leukemia (AML) and preclinical synergy with topoisomerase (topo) IIα inhibitors. We conducted a phase 1, dose-escalation study of selinexor with mitoxantrone, etoposide, and cytarabine (MEC) in 23 patients aged < 60 years with R/R AML. Due to dose-limiting hyponatremia in 2 patients on dose level 2 (selinexor 40 mg/m2), the maximum tolerated dose was 30 mg/m2. The most common grade ≥ 3 treatment-related non-hematologic toxicities were febrile neutropenia, catheter-related infections, diarrhea, hyponatremia, and sepsis. The overall response rate was 43% with 6 patients (26%) achieving complete remission (CR), 2 (9%) with CR with incomplete count recovery, and 2 (9%) with a morphologic leukemia-free state. Seven of 10 responders proceeded to allogeneic stem cell transplantation. The combination of selinexor with MEC is a feasibile treatment option for patients with R/R AML.Keywords
Funding Information
- Karyopharm Therapeutics
This publication has 25 references indexed in Scilit:
- Prognostic impact and targeting of CRM1 in acute myeloid leukemiaBlood, 2013
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaBlood, 2012
- Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaBlood, 2012
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsLeukemia, 2012
- mRNA export and cancerWIREs RNA, 2011
- Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimensLeukemia Research, 2011
- Second‐line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single‐center experienceAmerican Journal of Hematology, 2010
- Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)Journal of Clinical Oncology, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES maskingThe EMBO Journal, 1999